12-panel vs 17-panel drug test

A typical 12-panel covers THC, cocaine metabolites, amphetamines (including methamphetamine), opiates, PCP, benzodiazepines, barbiturates, methadone, oxycodone, MDMA, propoxyphene, and methaqualone — or a near-equivalent set with substitutions like buprenorphine in place of one of the obsolete analytes. The exact cutoff levels and analyte list vary by manufacturer; FDA's clearance database lists each cleared device's specific analytes and cutoffs.

For most non-DOT employer programs, the 12-panel is the right place to stop. It captures THC and cocaine for general drug-of-abuse screening, the SAMHSA-5 for parity with DOT-style programs, benzodiazepines and barbiturates for prescription-misuse signal, methadone and oxycodone for the most-misused prescription opioids, and MDMA for the recreational party-drug case. Beyond that, the marginal value of each added analyte falls off quickly relative to per-test cost and to the operational cost of MRO review.

The blind spots are real but predictable. The standard 12-panel does not include fentanyl, which has displaced heroin in most US markets and is now the leading driver of US overdose deaths according to CDC data. If your population is exposed to fentanyl — addiction medicine, harm reduction, sober living, county jails, forensic labs — you need either a 12-panel + fentanyl strip combination or a 14/17-panel that includes fentanyl natively. The standard 12-panel also misses buprenorphine, which is the cornerstone medication for medication-assisted treatment (MAT); MAT clinics monitoring patient compliance need buprenorphine on the panel.

If your program does not need to detect fentanyl, buprenorphine, synthetic cannabinoids, or TCAs, the 12-panel is the most cost-effective scope. If you do need any of those, do not try to extend a 12-panel with stacked strips — buy the right device once.

A 17-panel typically extends the 12-panel scope with fentanyl, buprenorphine, tramadol, tricyclic antidepressants, and synthetic cannabinoids (K2/spice). Exact composition varies by manufacturer; some 17-panels swap obsolete analytes like methaqualone or propoxyphene for newer concerns. Always confirm the analyte list and cutoffs against the device's FDA 510(k) clearance.

The single most defensible reason to step up to a 17-panel is fentanyl coverage. The CDC has reported that synthetic opioids — overwhelmingly illicit fentanyl and its analogs — are responsible for the majority of US overdose deaths in recent years. For any program where patient, client, or employee fentanyl exposure carries clinical or safety stakes, a panel without fentanyl is a meaningful blind spot. Standard opiate immunoassays do not reliably detect fentanyl because of structural differences; fentanyl needs a dedicated antibody.

Buprenorphine is the second defensible reason. SAMHSA recognizes buprenorphine as a frontline medication for opioid use disorder, and MAT clinics need to confirm that their patients are taking their prescribed buprenorphine and not diverting it. A 17-panel that includes buprenorphine lets a clinic verify compliance in a single device rather than running a separate buprenorphine-only strip.

The weaker arguments for a 17-panel are TCAs and synthetic cannabinoids. TCAs (tricyclic antidepressants) are rarely abused — they show up mainly in suicide-risk assessment, which is not what most workplace or even most rehab programs are scoped to do. Synthetic cannabinoids (K2/spice) are a real problem in specific populations — county jails, homeless-services intake, certain probation caseloads — but irrelevant for most office employers. If your population does not have those exposures, you are paying for analytes you will rarely see positive.